...
首页> 外文期刊>Oncology letters >Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
【24h】

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer

机译:CTEN的过表达与非小细胞肺癌中的吉替尼抗性有关

获取原文
获取原文并翻译 | 示例

摘要

COOH-terminus tensin-like molecule (CTEN) is a member of the tensin family, which is considered to be one of the novel proto-oncogenes involved in tumorigenesis and cancer progression. However, the mechanisms of CTEN in acquired resistance of non-small cell lung cancer (NSCLC) remain relatively unknown. The aim of the present study was to understand the roles of CTEN in acquired gefitinib resistance of NSCLC. The present study investigated the expression level of CTEN using reverse transcription-quantitative polymerase chain reaction and Western blot analysis. Cell Counting kit-8 and colony-formation assays were performed to evaluate the proliferative and colony-formative abilities of PC9 and PC9/GR cells in vitro. Mouse xenograft models were used to assess the growth of PC9/GR cells in vivo. A gefitinib-resistant NSCLC cell line (PC9/GR) was established, and the protein and mRNA expression levels of CTEN were observed to be higher in PC9/GR cells than in PC9 cells. Notably, the sensitivity of PC9/GR cells to gefitinib was observed to be decreased when CTEN was overexpressed, while PC9/GR cells with CTEN-downregulation showed markedly enhanced sensitivity to gefitinib. In vitro proliferation and colony formation assays revealed that increased CTEN markedly promoted the cell proliferative and colony-forming capacities of PC9 and PC9/GR cells, and CTEN-silencing inhibited the cell proliferative and colony-forming abilities of the PC9 and PC9/GR cells. Notably, deficient expression of CTEN notably retarded the growth of PC9/GR xenografts in vivo. In addition, the plasma mRNA expression of CTEN was notably elevated in patients with NSCLC with acquired gefitinib resistance. Overexpression of CTEN is associated with acquired gefitinib resistance in NSCLC. CTEN may be investigated as a potential therapeutic target for the treatment of patients with NSCLC with acquired gefitinib resistance.
机译:COOH末端张力蛋白样分子(CTEN)是张力蛋白家族的一员,被认为是参与肿瘤发生和发展的新型原癌基因之一。然而,CTEN在非小细胞肺癌(NSCLC)获得性耐药中的机制仍相对未知。本研究的目的是了解CTEN在非小细胞肺癌获得性吉非替尼耐药性中的作用。本研究采用逆转录定量聚合酶链反应和westernblot分析研究了CTEN的表达水平。采用细胞计数试剂盒-8和集落形成试验来评估PC9和PC9/GR细胞在体外的增殖和集落形成能力。小鼠异种移植模型用于评估PC9/GR细胞在体内的生长。建立了一个耐吉非替尼的非小细胞肺癌细胞系(PC9/GR),观察到PC9/GR细胞中CTEN的蛋白质和mRNA表达水平高于PC9细胞。值得注意的是,当CTEN过度表达时,PC9/GR细胞对吉非替尼的敏感性降低,而CTEN下调的PC9/GR细胞对吉非替尼的敏感性显著增强。体外增殖和集落形成实验表明,CTEN增加显著促进PC9和PC9/GR细胞的增殖和集落形成能力,CTEN沉默抑制PC9和PC9/GR细胞的增殖和集落形成能力。值得注意的是,CTEN表达不足显著阻碍了PC9/GR异种移植物在体内的生长。此外,在获得性吉非替尼耐药的非小细胞肺癌患者血浆CTEN mRNA表达显著升高。CTEN过度表达与NSCLC获得性吉非替尼耐药相关。CTEN可作为治疗非小细胞肺癌获得性吉非替尼耐药患者的潜在治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号